We are international

Jan Westin, M.D., Ph.D.
University Hospital
Lund, Sweden

Dr. Westin was educated and began his career in medicine at the University of Göteborg, Sweden. From 1990, he has practiced at the University of Lund, Sweden.

Dr. Westin started with scientific interest mainly in myeloproliferative disorders, cytogenetics, and other clinical aspects. He later switched interest to plasma cell disorders and specially multiple myeloma. Since 1985, he has mainly published papers in this field.

In 1987, started the Nordic Myeloma Study Group (NMSG), as a network of clinicians and scientists in the Scandinavian countries, with the primary goal to carry out large population-based phase III clinical trials. The scope of the group has widened to include other types of studies, a multitude of spin-off projects, development of common Nordic Guidelines for diagnosis and treatment of multiple myeloma (1995, revised edition 2002) and patient education efforts. Today, 17 university clinics and 95 county hospital clinics in Denmark, Norway and Sweden are associated with NMSG. The group has so far initiated 12 study protocols. Three randomized studies are at present running (comparison of two doses of IV pamidronate, melphalan-prednisone vs. melphalan-prednisone-thalidomide to patients > 65 yrs, VAD vs cyclophosphamide-dexamethasone as induction before high-dose therapy of patients < 65 yrs). The group has put special focus on quality of life-issues and health economics and included these aspects in all later studies.

During the years, Dr. Westin held a number of clinical and management positions in Gothenburg (Head of Hematology Section, Östra and Sahlgrenska Hospitals; Medical Director Östra Hospital; Medical Advisor to the Health Care Administration of the City of Göteborg) and Lund (Head of Department of Internal Medicine; Medical Advisor to the Region Skåne County Council, especially in R&D issues; Deputy Director Stem Cell Center, Faculty of Medicine, Lund University).

Currently, Dr. Westin is Clinical Hematologist Assistant Professor in Internal Medicine/Hematology at University Hospital in Lund, Sweden. His main interests are: • to further strengthen the Nordic Myeloma Study Group by running well-designed, population-based clinical trials with high accrual rate, giving generalizable results; to stimulate spin-off projects using the material from the main studies; to elucidate the role of patient information and patient participation in clinical decisions. • to expand the Nordic network into a European multinational Network of Excellence. • to stimulate and support younger colleagues to get involved in the clinical and experimental research focusing on plasma cell disorders, and in the clinical care of myeloma patients.

 related articles